|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Globocan 2008: Cancer incidence and
mortality worldwide. IARC CancerBase No. 10 Lyon, France: 2010,
http://globocan.iarc.fr.
Accessed August 31, 2011
|
|
2
|
Estimates 2012: Cancer incidence in
Brazil. INCA (National Cancer Institute); Rio de Janiero, Brazil:
pp. 34–35. 2012
|
|
3
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fleisher AS, Esteller M, Harpaz N, et al:
Microsatellite instability in inflammatory bowel disease-associated
neoplastic lesions is associated with hypermethylation and
diminished expression of the DNA mismatch repair gene, hMLH1.
Cancer Res. 60:4864–4868. 2000.
|
|
5
|
Lodish H, Berk A, Zipursky SL, Matsudaira
P, Baltimore D and Darnell J: Genetic analysis in molecular
biology. Cal and Molecular Biology. Nader HB: Rio de Janeiro:
Revinter; pp. 255–293. 2002
|
|
6
|
Hennig R, Ding XZ, Tong WG, Schneider MB,
Standop J, Friess H, Büchler MW, Pour PM and Adrian TE:
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human
pancreatic cancers but not in pancreatic ducts in normal tissue. Am
J Pathol. 161:421–428. 2002. View Article : Google Scholar
|
|
7
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygense in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steele VE, Holmes CA, Hawk ET, Kopelovich
L, Lubet RA, Crowell JA, Sigman CC and Kelloff GJ: Lipoxygenase
inhibitors as potential cancer chemopreventives. Cancer Epidemol
Biomarkers Prev. 8:467–483. 1999.PubMed/NCBI
|
|
9
|
Papafili A, Hill MR, Brull DJ, McAnulty
RJ, Marshall RP, Humphries SE and Laurent GJ: Common promoter
variant in cyclooxygenase-2 represses gene expression: evidence of
role in acute-phase inflammatory response. Arterioscler Thromb Vasc
Biol. 22:1631–1636. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, Miao X, Tan W, Ning B, Liu Z,
Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadluabar FF and
Lin D: Identification of functional genetic variants in
cyclooxygenase-2 and their association with risk of esophageal
cancer. Gastroenterology. 129:565–576. 2005.PubMed/NCBI
|
|
11
|
Borgeat P, Hamberg M and Samuelsson B:
Transformation of arachidonic acid homo-gamma-linoleic acid by
rabbit polymorphonuclear leuckocytes. Monohydroxy acids from novel
lipoxygenases. J Biol Chem. 251:7816–7820. 1976.
|
|
12
|
Pidgeon GP, Lysaght J, Krishnamoorthy S,
Reynolds JV, O’Byrne K, Nie D and Honn KV: Lipoxygenase metabolism:
roles in tumor progression and survival. Cancer Metastasis Rev.
26:503–524. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goel A and Boland CR: Recent insights into
the pathogenesis of colorectal cancer. Curr Opin Gastroenterol.
26:47–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fitzpatrick FA: Inflammation,
carcinogenesis, and cancer. Int Immunopharmacol. 1:1651–1667. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zell JA, Ziogas A, Bernstein L, Clarke CA,
Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G and
Anton-Culver H: Meat consumption, nonsteroidal anti-inflamatory
drug use, and mortality among colorectal cancer patients in the
California Teachers Study. Cancer Prev Res. 3:865–875. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Demarzo MM, Martins LV, Fernandes CR,
Herrero FA, Perez SE, Turatti A and Garcia SB: Exercise reduces
inflammation and cell proliferation in rat colon carcinogenesis.
Med Sci Sports Exerc. 40:618–621. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baron JA, Cole BF, Sandler RS, et al: A
randomized trial of aspirin to prevent colorectal adenomas. N Engl
J Med. 348:891–898. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pandey S, Mittal RD, Srivastava M,
Srivastava K and Mittal B: Cyclooxygenase-2 gene polymorphisms and
risk of cervical cancer in a North Indian population. Int J Gynecol
Cancer. 20:625–630. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hirano T: Alcohol consumption and
oxidative DNA damage. Int J Environ Res Public Health. 8:2895–2906.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoff JH, te Morsche RH, Roelofs HM, van
der Logt EM, Nagengast FM and Peters WH: COX-2 polymorphisms
−765G-->C and −1195A-->G and colorectal cancer risk. World J
Gastroenterol. 15:4561–4565. 2009.
|
|
21
|
Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY,
Li J, Luo Y and Zhang X: Cyclooxygenase 2 polymorphism and
colorectal cancer: −765G>C variant modifies risk associated with
smoking and body mass index. World J Gastroenterol. 14:1785–1789.
2008.
|
|
22
|
Wang CH, Wu KH, Yang YL, Peng CT, Wang RF,
Tsai CW, Tsai RY, Lin DT, Tsai FJ and Bau DT: Association study of
cyclooxygenase 2 single nucleotide polymorphisms and childhood
acute lymphoblastic leukemia in Taiwan. Anticancer Res.
30:3649–3653. 2010.PubMed/NCBI
|
|
23
|
Gangwar R, Mandhani A, Mittal RD and
Pradesh U: Functional polymorphisms of cyclooxygenase-2 (COX-2)
gene and risk for urinary bladder cancer in North India. Surgery.
149:126–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Piranda DN, Festa-Vasconcellos JS, Amaral
LM, Bergmann A and Vianna-Jorge R: Polymorphisms in regulatory
regions of Cyclooxygenase-2 gene and breast cancer risk in
Brazilians: a case-control study. BMC Cancer. 10:6132010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang Y, Liu JL, Wu Y, Zhang ZY and Wu R:
Cyclooxygenase-2 polymorphisms and susceptibility to esophageal
cancer: a meta-analysis. Tohoku J Exp Med. 223:137–144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Biramijamal F, Basatvat S, Hossein-Nezhad
A, Soltani MS, Akbari Noghabi K, Irvanloo G and Shamimi K:
Association of COX-2 promoter polymorphism with gastrointestinal
tract cancer in Iran. Biochem Genet. 48:915–923. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akkız H, Bayram SI, Bekar A, Akgöllü E and
Ülger Y: Functional polymorphisms of cyclooxygenase-2 gene and risk
for hepatocellular carcinoma. Mol Cell Biochem. 347:201–208.
2011.PubMed/NCBI
|
|
28
|
Sitarz R, Leguit RJ, de Leng WW, Polak M,
Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ and Milne AN: The
COX-2 promoter polymorphism −765 G>C is associated with
early-onset, conventional and stump gastric cancers. Mod Pathol.
21:685–690. 2008.
|
|
29
|
Kristinsson JO, van Westerveld P, te
Morsche RH, Roelofs HM, Wobbes T, Witteman BJ, Tan AC, van Oijen
MG, Jansen JB and Peters WH: Cyclooxygenase-2 polymorphisms and the
risk of esophageal adeno- or squamous cell carcinoma. World J
Gastroenterol. 15:3493–3497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peters WH, Lacko M, Te Morsche RH, Voogd
AC, Oude Ophuis MB and Manni JJ: COX-2 polymorphisms and the risk
for head and neck cancer in white patients. Head Neck. 31:938–943.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
In KH, Asano K, Beier D, Grobholz J, et
al: Naturally occurring mutations in the human 5-lipoxygenase gene
promoter that modify transcription factor binding and reporter gene
transcriptions. J Clin Invest. 99:1130–1137. 1997. View Article : Google Scholar
|
|
32
|
Jiang WG, Douglas-Jones A and Mansel RE:
Levels of expression of lipoxygenases and cyclooxygenase-2 in human
breast cancer. Prostaglandins Leukot Essent Fatty Acids.
69:275–281. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Soumaoro LT, Iida S, Uetake H, Ishiguro M,
Takagi Y, Higuchi T, Yasuno M, Enomoto M and Sugihara K: Expression
of 5-Lipoxygenase in human colorectal cancer. World J
Gastroenterol. 39:6355–6360. 2006.PubMed/NCBI
|
|
34
|
Wang J, John EM and Ingles SA:
5-lipoxygenase and 5-lipoxygenase-activating protein gene
polymorphisms, dietary linoleic acid, and risk for breast cancer.
Cancer Epidemiol Biomarkers Prev. 17:2748–2754. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen M, Vermeulen R, Rajaraman P, Menashe
I, He X, Chapman RS, Yeager M, Thomas G, Burdett L, Hutchinson A,
Yuenger J, Chanock S and Lan Q: Polymorphisms in innate immunity
genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen.
50:285–290. 2009. View
Article : Google Scholar : PubMed/NCBI
|
